SH3TC2-DT

Across TCGA pan-cancer cohorts, SH3TC2-DT RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of SH3TC2-DT’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where SH3TC2-DT RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SH3TC2-DT is over-expressed in tumor, although a few such as UCEC and BRCA show the opposite, repressed pattern.

BLCA, COAD, and UCEC are the cancer types where SH3TC2-DT tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SH3TC2-DT RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	Male	All	+0.390	<.001	9	view →
COAD	All	II,III,IV	+0.139	<.001	7	view →
UCEC	All	All	−0.084	.008	6	view →
BRCA	All	III,IV	−0.068	<.001	6	view →
HNSC	All	III,IV	+0.082	.005	5	view →
KIRP	All	II,III,IV	+0.040	.015	5	view →
LUSC	Male	All	+0.079	.002	4	view →
THCA	All	All	+0.013	.014	4	view →
KICH	Female	All	−0.024	.001	3	view →
LIHC	All	All	+0.005	.002	3	view →
KIRC	Male	All	+0.021	.016	2	view →
READ	All	All	+0.133	.020	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

SH3TC2-DT–BLCA

Open the BLCA breakdown →